Search Results - application+%3e+therapeutics

784 Results Sort By:
Human Antibodies Targeting Beneficial Viral Peptide in Liver Cancer
Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees to develop a collection of anti-CE1 antibodies for liver cancer treatment. Description of Technology: Liver cancer is the sixth most common and the third leading cause of cancer death worldwide. The most common liver cancer in adults is hepatocellular...
Published: 7/31/2026   |   Updated: 7/31/2026   |   Inventor(s): Mitchell Ho, Zhijian Duan, Jesse Buffington, Xin Wei Wang, Man Hsin Hung, Limin Wang
Keywords(s):  
Category(s): Application > Therapeutics, TherapeuticArea > Gastroenterology, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing
Characterization of novel pan anti-HLA antibodies that block LILR inhibitory receptors and activate anti-tumor immunity
Cancer immunotherapy has transformed treatment for some patients, but many tumors still do not respond well to current options, including checkpoint inhibitors. Researchers at NIAID’s Laboratory of Immune System Biology (LISB) have developed new antibodies designed to help the immune system fight tumors. These lab-made antibodies, called pan-anti-HLA...
Published: 7/16/2026   |   Updated: 7/16/2026   |   Inventor(s): David Margulies, Abir Panda, Ethan Shevach, Kannan Natarajan, Patricia Korty
Keywords(s):  
Category(s): Application, Application > Therapeutics, Collaboration Sought, TherapeuticArea, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease
RS-1 Knockout Mouse Model for X-Linked Retinoschisis (XLRS) Research
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a transgenic mouse model for X-linked retinoschisis (XLRS). This technology includes a transgenic mouse model specifically designed to study X-linked retinoschisis (XLRS) disease by interrupting exon 1 of the Rs1 gene. XLRS is a genetic condition...
Published: 6/24/2026   |   Updated: 6/24/2026   |   Inventor(s): Paul Sieving, Yong Zeng, Ronald Bush
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Animal Models, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases
Gene Therapy for Leber Congenital Amaurosis
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV gene therapy for Leber Congenital Amaurosis caused by CEP290 mutations. This technology includes an innovative gene therapy approach for treating Leber congenital amaurosis (LCA) caused by CEP290 mutations. LCA is a severe inherited...
Published: 6/18/2026   |   Updated: 6/16/2026   |   Inventor(s): Zhijian Wu, Anand Swaroop, Suddhasil Mookherjee, Suja Hiriyanna
Keywords(s):  
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Plasmids/Vectors, ResearchProducts > Sequences, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases
Innovative Gene Therapy for Retinal Diseases
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative gene therapy for retinal diseases. This technology includes an innovative gene therapy approach aimed at treating retinal diseases, which are a leading cause of vision loss. Retinal diseases, such as age-related macular degeneration...
Published: 6/18/2026   |   Updated: 6/16/2026   |   Inventor(s): Susan Gentleman, Thomas Redmond
Keywords(s):  
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Plasmids/Vectors, ResearchProducts > Virus/Bacteria, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases
Advanced Gene Editing Technology for Therapeutic Applications
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of advanced gene editing technology for therapeutic applications. This technology includes advanced gene editing techniques aimed at developing targeted therapies for genetic disorders. Current treatments for many genetic conditions are limited,...
Published: 6/18/2026   |   Updated: 6/16/2026   |   Inventor(s): Ruchi Sharma, Kapil Bharti
Keywords(s):  
Category(s): Application > Therapeutics, Application > Research Materials, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Plasmids/Vectors, ResearchProducts > Sequences, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases
Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a stable cell line for the production of human Retinoschisin (RS1) for therapeutic applications in ocular diseases. This technology includes the development of a stable cell line for the large-scale production of human Retinoschisin (RS1),...
Published: 6/18/2026   |   Updated: 6/16/2026   |   Inventor(s): Paul Sieving, Alaknanda MIshra, Vijayasarathy Camasamudram, Lisa Wei
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Human Cell Lines, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases
Immunosuppressive Exosomes for Treating Autoimmune Diseases
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of immunosuppressive exosomes derived from IL-35 and IL-27 producing Bregs as a therapeutic treatment for autoimmune diseases. This technology includes the use of exosomes derived from Interleukin 35 (IL-35) and Interleukin 27 (IL-27) producing...
Published: 6/18/2026   |   Updated: 6/16/2026   |   Inventor(s): Minkyung Kang, Charles Egwuagu
Keywords(s):  
Category(s): Application, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Carriers/Adjuvants, TherapeuticArea > Immunology, TherapeuticArea > Neurology, TherapeuticArea > Ophthalmology
Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative therapeutic strategies targeting myocilin mutations in glaucoma. This technology includes the development of HEK293 cell lines expressing wild-type and Y437H mutant myocilin, which can be used to study the pathogenic mechanisms...
Published: 6/18/2026   |   Updated: 6/16/2026   |   Inventor(s): Myungkuk Joe
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Human Cell Lines, TherapeuticArea > Ophthalmology
A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells for targeted therapies and drug discovery. This technology includes a robust method to generate macular and peripheral retinal pigment epithelium (RPE)...
Published: 6/18/2026   |   Updated: 6/16/2026   |   Inventor(s): Kapil Bharti, Fnu Ruchi, Davide Ortolan
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Human iPSC Lines, ResearchProducts > Human Cell Lines, TherapeuticArea > Ophthalmology, TherapeuticArea > Geriatrics
1 2 3 4 5 6 7 8 9 10 ...